Gedeon Richter announces withdrawal of its MA for biosimilar pegfilgrastim.
Home / Search Results
Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.
By Bioblast Editor | Dec 19, 2016
Gedeon Richter announces withdrawal of its MA for biosimilar pegfilgrastim.
By Bioblast Editor | Dec 16, 2016
Samsung Bioepis receives positive CHMP opinion for its application for indication extension of Benepali® (etanercept) to include juvenile idiopathic arthritis and pediatric plaque psoriasis.
By Bioblast Editor | Dec 15, 2016
The results of two Regeneron ph III studies published in the New England Journal of Medicine report that dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, improved the signs and symptoms of atopic dermatitis, symptoms of anxiety and depression, an...
By Bioblast Editor | Dec 02, 2016
Amgen/Allergan submit EMA application for biosimilar adalimumab.
By Bioblast Editor | Nov 25, 2016
Commercial (at risk) launch by Pfizer/Celltrion of Inflectra® (infliximab-dyyb).
By Bioblast Editor | Nov 15, 2016
Amgen and Allergan submit BLA for ABP 215, bevacizumab biosimilar. Read more
By Bioblast Editor | Oct 25, 2016
Sandoz indicates it plans to conduct further studies with a target of 2018 for further submissions to the FDA.
By Bioblast Editor | Oct 06, 2016
FDA accepts Coherus BioSciences 351(k) filing for pegfilgrastim.
By Bioblast Editor | Oct 06, 2016
Teva and Celltrion announce exclusive marketing deal under which Teva will commercialise Celltrion’s biosimilar rituximab and trastuzumab products in the US and CA.
By Bioblast Editor | Oct 03, 2016
Samsung application for SB3, biosimilar trastuzumab accepted for review by EMA.
SUBSCRIBE TO PEARCE IP